Cassava Sciences Q3 net loss $10.8M; advances simufilam for TSC epilepsy

FILANA THERAPEUTICS, INC.

2025-Q3 EPS reported -$1.62

Net loss of $10.8M ($0.22/share) vs $27.9M loss ($0.58) in Q3 2024; cash $106.1M.
Simufilam proof-of-concept study for TSC-related epilepsy expected to begin H1 2026.
Appointed Joseph Hulihan as CMO (August 2025) and Dawn C. Bir to board (October 2025).
Maintains $31.25M loss contingency for securities litigation settlement; timing unclear.
Cash use guidance for second half 2025 revised downward; year-end cash est. $92-$96M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.